PolyPeptide Group AG – SIX:PPGN.SW
PolyPeptide Group AG stock price today
PolyPeptide Group AG stock price monthly change
PolyPeptide Group AG stock price quarterly change
PolyPeptide Group AG stock price yearly change
PolyPeptide Group AG key metrics
Market Cap | 943.33M |
Enterprise value | 608.75M |
P/E | 14.90 |
EV/Sales | 2.15 |
EV/EBITDA | 7.30 |
Price/Sales | 2.57 |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.32 |
Revenue | 601.35M |
EBITDA | 20.74M |
Income | -43.67M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 3.45% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePolyPeptide Group AG stock price history
PolyPeptide Group AG stock forecast
PolyPeptide Group AG financial statements
| Jun 2022 | 133.65M | 10.24M | 7.67% |
|---|---|---|---|
| Dec 2022 | 147.32M | -2.48M | -1.68% |
| Jun 2023 | 131.83M | -34.26M | -25.99% |
| Dec 2023 | 188.53M | -17.17M | -9.11% |
| 2025 | 411.19M | 14.89M | 3.62% |
|---|---|---|---|
| 2026 | 486.97M | 38.43M | 7.89% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | 1.15% |
| 2023 |
| Jun 2022 | 579253000 | 151.94M | 26.23% |
|---|---|---|---|
| Dec 2022 | 575782000 | 154.10M | 26.76% |
| Jun 2023 | 589123000 | 204.80M | 34.76% |
| Dec 2023 | 689088000 | 307.86M | 44.68% |
| Jun 2022 | -7.65M | -41.20M | -23.45M |
|---|---|---|---|
| Dec 2022 | 13.11M | -37.23M | -3.41M |
| Jun 2023 | -48.32M | -31.09M | 53.48M |
| Dec 2023 | 84.80M | -28.41M | 31.06M |
PolyPeptide Group AG alternative data
| Aug 2023 | 1,219 |
|---|---|
| Sep 2023 | 1,181 |
| Oct 2023 | 1,181 |
| Nov 2023 | 1,181 |
| Dec 2023 | 1,181 |
| Jan 2024 | 1,181 |
| Feb 2024 | 1,181 |
| Mar 2024 | 1,273 |
| Apr 2024 | 1,273 |
| May 2024 | 1,273 |
| Jun 2024 | 1,273 |
| Jul 2024 | 1,273 |
PolyPeptide Group AG other data
-
What's the price of PolyPeptide Group AG stock today?
One share of PolyPeptide Group AG stock can currently be purchased for approximately $80.45.
-
When is PolyPeptide Group AG's next earnings date?
Unfortunately, PolyPeptide Group AG's (PPGN.SW) next earnings date is currently unknown.
-
Does PolyPeptide Group AG pay dividends?
Yes, PolyPeptide Group AG pays dividends and its trailing 12-month yield is 1.37% with 0% payout ratio. The last PolyPeptide Group AG stock dividend of undefined was paid on 6 Sep 2025.
-
How much money does PolyPeptide Group AG make?
PolyPeptide Group AG has a market capitalization of 943.33M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14.02% to 320.37M US dollars.
-
What is PolyPeptide Group AG's stock symbol?
PolyPeptide Group AG is traded on the SIX under the ticker symbol "PPGN.SW".
-
What is PolyPeptide Group AG's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of PolyPeptide Group AG?
Shares of PolyPeptide Group AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does PolyPeptide Group AG have?
As Jul 2024, PolyPeptide Group AG employs 1,273 workers.
-
When PolyPeptide Group AG went public?
PolyPeptide Group AG is publicly traded company for more then 4 years since IPO on 28 Apr 2021.
-
What is PolyPeptide Group AG's official website?
The official website for PolyPeptide Group AG is polypeptide.com.
-
How can i contact PolyPeptide Group AG?
PolyPeptide Group AG can be reached via phone at +41 41 723 20 34.
PolyPeptide Group AG company profile:
PolyPeptide Group AG
polypeptide.comSIX
1,277
Drug Manufacturers - Specialty & Generic
Healthcare
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Zug, 6300
:
ISIN: CH1110760852
:
